# Report: 8_Gliosis_hypoxia (run_1.md)

**Cell type:** glioblastoma cells
**Disease:** glioblastoma multiforme (GBM)
**Tissue:** brain

## Program Summaries
### Hypoxia-Driven Angiogenesis
HIF-1α-dependent pathway driving vascular endothelial growth factor (VEGF) expression, vessel density increases, and hypoxic adaptation in glioblastoma. This program enables tumor cells to promote neovascularization in response to inadequate oxygen tension, supporting rapid tumor growth despite poor vascularization.

**Predicted impacts:**
- Increased expression of pro-angiogenic factors (VEGF, ANGPTL4) promoting microvessel density
- Enhanced metabolic adaptation to hypoxic stress through autophagy induction
- Survival advantage in tumor core regions with limited oxygen availability
- Reduced dependence on vasculature for nutrient supply through metabolic shift

**Supporting genes:** HILPDA, NOX4, HMOX1, BNIP3L, PTGS2, ANGPTL4, GPC5, TRIB3

**References:** [15], [3], [5], [9]

**Biological processes:**
- HIF-1α stabilization and activation: HILPDA, NOX4, HMOX1, BNIP3L
- VEGF-mediated angiogenesis and vascular patterning: PTGS2, ANGPTL4, GPC5
- Autophagy induction under hypoxia: BNIP3L, TRIB3

**Cellular components:**
- Hypoxic microenvironment sensing apparatus: NOX4, HMOX1
- Extracellular matrix vascular niche: ANGPTL4, GPC5

**Reference notes:**
- Foundational review of HIF-1α pathway in gliomas with mechanisms of activation and downstream targets
- Recent 2025 study demonstrating HIF-1α mediated regulation of GBM malignant behaviors with experimental validation
- Detailed analysis of HIF-1α dependent autophagy induction through BNIP3/BNIP3L axis and immune modulation
- Role of COX-2/PGE2 in angiogenesis and immune regulation in GBM tumor microenvironment

### Epithelial-Mesenchymal Transition and Invasion
Coordinated remodeling of cell-cell adhesion, extracellular matrix composition, and cytoskeletal architecture enabling glioblastoma cells to acquire migratory and invasive capacity. This program involves loss of epithelial markers (E-cadherin, claudins) and gain of mesenchymal markers (N-cadherin, vimentin, MMPs), facilitating tumor cell dissemination and invasion of surrounding brain parenchyma.

**Predicted impacts:**
- Enhanced extracellular matrix degradation through increased MMP secretion
- Increased migratory velocity and invasive capacity through actin reorganization
- Altered expression of adhesion molecules (reduced E-cadherin, increased N-cadherin)
- Enhanced integrin-mediated signaling driving survival and proliferation signals
- Immune evasion through altered glycosylation of cell surface molecules
- Reduced responsiveness to contact inhibition signals

**Supporting genes:** COL5A1, COL13A1, COL24A1, LTBP2, ABI3BP, CHSY3, NDRG1, FAT4, GCNT1, ITGB3, ABLIM3, CAV1, EPHA3, SPNS2, PRKCH, GRK5

**References:** [18], [24], [33], [47], [48]

**Biological processes:**
- Extracellular matrix remodeling and collagen crosslinking: COL5A1, COL13A1, COL24A1, LTBP2, ABI3BP, CHSY3
- Loss of cell-cell adhesion and E-cadherin function: NDRG1, FAT4, GCNT1
- Acquisition of migratory and invasive phenotype: ITGB3, ABLIM3, CAV1, EPHA3, SPNS2
- Glycosylation of cell surface molecules: GCNT1, CHSY3, MGAM

**Cellular components:**
- Focal adhesions and integrin-ECM interfaces: ITGB3, FAT4, ABI3BP, ABLIM3
- Extracellular matrix protein scaffold: COL5A1, COL13A1, COL24A1, LTBP2, CHSY3
- Actin-myosin contractile apparatus: ABLIM3, PRKCH, GRK5

**Reference notes:**
- COL5A1 is identified as a novel prognostic target and therapeutic target through the PPRC1-ESM1 axis
- NDRG1 acts as tumor suppressor by inhibiting EMT and promoting E-cadherin expression
- Comprehensive analysis of integrin pathways in GBM metastasis and chemoresistance
- ECM stiffness and remodeling drive invasion and metastasis through MMP-mediated degradation
- O-linked glycan alterations in GBM exploit immune modulation through altered glycocode

### Aberrant Receptor Tyrosine Kinase Signaling
Dysregulation of multiple receptor tyrosine kinases (RTKs) including MET, EGFR, and Eph receptors driving constitutive activation of downstream proliferation and survival pathways. These receptors activate PI3K/AKT/mTOR and MAPK/ERK cascades, promoting glioblastoma cell growth, survival, and acquisition of drug resistance.

**Predicted impacts:**
- Constitutive activation of survival and proliferation signals
- Enhanced chemotherapy and radiotherapy resistance through DNA repair pathway activation
- Increased glucose uptake and metabolic reprogramming
- Promotion of glioma stem cell self-renewal and maintenance
- Enhanced invasive capacity through EMT-associated pathways
- Reduced dependence on growth factor availability

**Supporting genes:** MET, EPHA3, EPHA1-AS1, PRKCH, GRK5, ERRFI1

**References:** [16], [17], [3], [56]

**Biological processes:**
- MET receptor activation and hepatocyte growth factor signaling: MET
- Eph receptor signaling and cell adhesion: EPHA3, EPHA1-AS1
- Downstream PI3K/AKT/mTOR cascade activation: PRKCH, GRK5, ERRFI1
- MAPK/ERK pathway activation: ERRFI1, GRK5

**Cellular components:**
- Plasma membrane receptor complexes: MET, EPHA3, EPHA1-AS1
- Intracellular signaling transducers: PRKCH, GRK5, ERRFI1

**Reference notes:**
- Recent 2024 comprehensive review of MET receptor dysregulation in GBM with targeted therapy strategies
- 2025 review of Eph/ephrin signaling in CNS tumors, identifying EphA2/A3 as key therapeutic targets
- Detailed mechanism of RTK-mediated HIF-1α stabilization through PI3K/AKT/mTOR pathway
- ERRFI1 differential regulation of EGFR and AKT pathways based on receptor expression level

### Inflammatory Signaling and Immune Evasion
Coordinated upregulation of cyclooxygenase-2 and prostaglandin E2 signaling coupled with exploitation of altered glycosylation patterns to evade immune surveillance. This program enables glioblastoma cells to create an immunosuppressive tumor microenvironment by recruiting and polarizing immune cells toward protumorigenic phenotypes.

**Predicted impacts:**
- Robust production of immunosuppressive mediators (IL-6, IL-10, GM-CSF)
- Preferential recruitment of protumorigenic macrophages and myeloid-derived suppressor cells
- Downregulation of MHC class II reducing T-cell activation capacity
- Enhanced tumor cell survival against immune attack through altered glycocode recognition
- Induction of regulatory T cells further dampening antitumor immunity
- Increased resistance to immune checkpoint inhibitor therapy

**Supporting genes:** PTGS2, HMOX1, NOX4, GCNT1, CHSY3, MX2

**References:** [12], [15], [37], [47]

**Biological processes:**
- COX-2/PGE2 axis-driven inflammation: PTGS2
- Prostaglandin-mediated immune cell recruitment and polarization: PTGS2, HMOX1
- Glycan-mediated immune modulation: GCNT1, CHSY3
- Antigen presentation suppression: PTGS2, HMOX1, MX2

**Cellular components:**
- Prostaglandin signaling receptors: PTGS2, PDE4C
- Glycan biosynthetic machinery: GCNT1, CHSY3
- Oxidative stress response organelles: HMOX1, NOX4

**Reference notes:**
- Comprehensive review of COX-2 in GBM proliferation, apoptosis, invasion, angiogenesis, and immunosuppression
- Detailed analysis of COX-2/PGE2 pleotropic effects on glioma-associated microglia dynamics and tumor progression
- Evidence that glioblastomas exploit truncated O-linked glycans for immune evasion through MGL-L ligand accumulation
- Microglia-induced interferon-stimulated genes mediate chemotherapy resistance through STAT1 signaling

### Autophagy and Cellular Stress Response
Activation of macroautophagy and selective autophagy pathways in response to metabolic stress, hypoxia, and endoplasmic reticulum stress. This program enables glioblastoma cells to maintain survival under nutrient-poor conditions, contributes to therapy resistance, and regulates immune cell infiltration.

**Predicted impacts:**
- Enhanced survival under nutrient deprivation through selective protein degradation
- Increased resistance to hypoxic stress through metabolic reprogramming
- Enhanced chemotherapy and radiotherapy resistance through autophagy-mediated survival
- Suppression of anti-tumor immune responses through autophagy-mediated degradation of immune effector molecules
- Maintenance of glioma stem cell phenotype through selective autophagy
- Metabolic adaptability enabling rapid response to microenvironmental changes

**Supporting genes:** BNIP3L, TRIB3, HMOX1, AMPD3

**References:** [19], [24], [9]

**Biological processes:**
- HIF-1α dependent autophagy initiation: BNIP3L, TRIB3
- TRIB3-mediated autophagy inhibition restraint: TRIB3
- Metabolic adaptation through protein degradation: BNIP3L, TRIB3, AMPD3
- Endoplasmic reticulum stress-induced autophagy: TRIB3, HMOX1

**Cellular components:**
- Autophagosomes and autophagolysosomes: BNIP3L, TRIB3
- Endoplasmic reticulum stress sensors: TRIB3, HMOX1

**Reference notes:**
- Comprehensive review of hypoxia-associated pathways including autophagy induction and immune suppression
- TRIB3 identified as facilitator of GBM progression through autophagy regulation
- Cilengitide-induced autophagy reduces GBM cell survival and enhances radiosensitivity

### Integrin-Mediated Cell Adhesion and Survival
Dysregulated integrin-extracellular matrix interactions promoting cell survival, proliferation, and drug resistance through activation of focal adhesion kinase and associated survival pathways. Integrin αvβ3 and α5β1 are particularly important in glioblastoma, mediating interactions with vitronectin, fibronectin, and other matrix proteins.

**Predicted impacts:**
- Enhanced GSC maintenance and self-renewal through focal adhesion signaling
- Increased chemotherapy resistance through anchorage-independent survival signals
- Reduced sensitivity to cell detachment-induced apoptosis (anoikis)
- Enhanced migration and invasion through integrin-mediated adhesion
- Metabolic reprogramming through integrin-AKT signaling
- Promotion of GSC differentiation or stemness maintenance depending on matrix composition

**Supporting genes:** ITGB3, FAT4, ABLIM3, ANGPTL4, COL5A1, COL13A1, COL24A1, LTBP2

**References:** [24], [29], [35], [8]

**Biological processes:**
- Integrin αvβ3 and α5β1 ligand binding and signaling: ITGB3
- Focal adhesion kinase and downstream signaling: ITGB3, FAT4, ABLIM3
- Anoikis resistance and anchorage-independent survival: ANGPTL4, ITGB3
- Cilengitide-sensitive autophagy induction: ITGB3, BNIP3L

**Cellular components:**
- Integrin heterodimers on cell surface: ITGB3
- Focal adhesion complexes: ITGB3, FAT4, ABLIM3
- Extracellular matrix protein ligands: COL5A1, COL13A1, COL24A1, LTBP2

**Reference notes:**
- Comprehensive review of integrin roles in GBM metastasis and chemoresistance
- ANGPTL4 promotes anoikis resistance and invasion through integrin β1 signaling and MMP-1 upregulation
- Integrin αvβ3 is therapeutically targetable through cilengitide
- Vitronectin is highly expressed ECM component in adult GBM

### Metabolic Enzyme Dysregulation
Altered expression of glycolytic, lipid metabolic, and amino acid metabolic enzymes supporting rapid tumor growth and adaptation to hypoxic and nutrient-poor conditions. Dysregulation includes increased glucose transporter expression, glycogen accumulation pathways, and enhanced fatty acid oxidation.

**Predicted impacts:**
- Enhanced energy production through multiple metabolic pathways (glycolysis, fatty acid oxidation, glutaminolysis)
- Rapid adaptation to hypoxic conditions through metabolic switching
- Reduced sensitivity to metabolic pathway inhibitors through metabolic redundancy
- Increased nucleotide production supporting rapid proliferation
- Enhanced survival under nutrient-poor conditions through alternative metabolic routes
- Adaptation to antiangiogenic therapy through metabolic reprogramming

**Supporting genes:** MGAM, PPP1R3C, EHHADH, SLC39A14, SLC6A6, AMPD3

**References:** [24], [31], [9]

**Biological processes:**
- Carbohydrate metabolism and glycogen accumulation: MGAM, PPP1R3C
- Fatty acid oxidation: EHHADH, SLC39A14
- Amino acid transport and metabolism: SLC39A14, SLC6A6
- Purine/nucleotide metabolism: AMPD3

**Cellular components:**
- Glycolytic and glycogenolytic enzymes: MGAM, PPP1R3C
- Beta-oxidation pathway enzymes: EHHADH
- Nutrient transporters: SLC39A14, SLC6A6

**Reference notes:**
- Analysis of fatty acid oxidation-related subtypes in cancer showing metabolic shifts and therapy resistance
- HIF-1α modulation of adenosine metabolism affecting immune cell function and tumor progression
- Glut-3 addiction in GSCs as metabolic vulnerability

### Long Non-Coding RNA Regulatory Networks
Dysregulation of multiple long non-coding RNAs that regulate glioblastoma cell proliferation, invasion, drug resistance, and stem cell maintenance. These lncRNAs function as competing endogenous RNAs, scaffold proteins, and transcriptional regulators modulating key oncogenic pathways.

**Predicted impacts:**
- Enhanced RAS pathway signaling driving proliferation and invasion
- Dysregulated microRNA function through competing endogenous RNA networks
- Altered transcriptional landscape supporting GSC maintenance
- Enhanced drug resistance through regulation of ABC transporters
- Promotion of epithelial-mesenchymal transition phenotypes
- Increased tumor aggressiveness and invasion capacity

**Supporting genes:** LUCAT1, LINC02615, POT1-AS1, LINC01705, LINC01376, LINC00240, AC051619.5, AC083837.1, AC092944.1, AC008014.1, AL158064.1, AL390957.1, AC099681.1, VLDLR-AS1, EPHA1-AS1, NECTIN3-AS1, RPL34-AS1, OSMR-AS1, RNF217-AS1, AP006545.3, AP001528.1, LINC02340

**References:** [36], [39]

**Biological processes:**
- LUCAT1-mediated RAS pathway promotion: LUCAT1
- lncRNA-mediated competing endogenous RNA networks: LUCAT1, LINC02615, POT1-AS1, LINC01705
- lncRNA-mediated transcriptional regulation: LUCAT1, LINC01376, LINC00240

**Cellular components:**
- Nuclear ribonucleoprotein complexes: LUCAT1, LINC02615, POT1-AS1

**Reference notes:**
- LUCAT1 regulates RAS pathway and ABCB1-mediated drug resistance in malignant glioma
- LUCAT1 promotes GSC self-renewal and identified as therapeutic target in GBM

### Transcriptional Control of Differentiation and Stemness
Dysregulation of transcription factors and co-regulators controlling glioblastoma stem cell maintenance versus differentiation transitions. RUNX2 drives malignant progression through increased proliferation and expression of invasion-associated genes, while NDRG1 acts as a metastasis suppressor maintaining differentiated epithelial phenotype.

**Predicted impacts:**
- RUNX2-driven increase in proliferative capacity and expression of invasion-associated MMPs
- NDRG1 loss associated with EMT transition, increased invasiveness, and poor prognosis
- RCAN2-mediated effects on differentiation through calcineurin-NFAT axis
- Context-dependent growth effects of ERRFI1 based on EGFR expression level
- Dysregulation of cell cycle checkpoint control
- Altered response to differentiation signals

**Supporting genes:** RUNX2, NDRG1, RCAN2, ERRFI1, FAT4

**References:** [2], [33], [38], [56]

**Biological processes:**
- RUNX2-mediated malignant progression: RUNX2
- NDRG1-mediated tumor suppression and differentiation: NDRG1
- RCAN2 regulation of calcineurin-NFAT signaling: RCAN2
- ERRFI1 context-dependent regulation of growth: ERRFI1

**Cellular components:**
- Transcription factor protein complexes: RUNX2, RCAN2, ERRFI1
- Cell adhesion molecule complexes: NDRG1, FAT4

**Reference notes:**
- RUNX2 promotes malignant progression in glioma through cross-talk with cAMP/PKA signaling
- Comprehensive review of NDRG1 as critical regulator of differentiation and invasion in GBM
- RCAN2 as p53-regulated gene influencing cancer progression through calcineurin signaling
- ERRFI1 dual mechanism in AKT and EGFR pathway regulation based on receptor expression

### Redox Homeostasis and Oxidative Stress Response
Dysregulation of antioxidant defense systems and oxidative stress sensors affecting tumor progression, drug resistance, and immune evasion. HO-1 and NOX4 represent dual-faced regulators that maintain cellular redox balance while promoting cancer progression through complex, context-dependent mechanisms.

**Predicted impacts:**
- Enhanced cellular survival under oxidative stress conditions
- Reduced response to ROS-generating chemotherapy agents
- Nuclear HO-1 translocation associated with poor prognosis and therapy resistance
- NOX4-derived ROS driving metabolic reprogramming and FOXM1 expression
- ANGPTL4-mediated anoikis resistance through ROS-dependent signaling
- Altered immune cell function through ROS modulation and adenosine accumulation

**Supporting genes:** HMOX1, NOX4, ANGPTL4

**References:** [10], [7], [8]

**Biological processes:**
- HO-1 mediated cytoprotection and apoptosis resistance: HMOX1
- NOX4-derived ROS and metabolic reprogramming: NOX4
- ANGPTL4-mediated ROS generation and survival signaling: ANGPTL4

**Cellular components:**
- Heme oxygenase-1 enzyme and products: HMOX1
- NADPH oxidase complex: NOX4, ANGPTL4

**Reference notes:**
- Comprehensive review of HO-1 role in tumorigenesis with dual pro- and anti-survival functions
- NOX4-derived ROS in cancer development and progression
- ANGPTL4-mediated ROS generation through Nox1 activation

### Extracellular Matrix Composition and Immune Targeting
Dysregulation of glycosaminoglycan and proteoglycan synthesis enzymes altering extracellular matrix composition to promote immune evasion and support tumor growth. This program involves specific glycosylation modifications that reduce immune recognition while maintaining structural integrity of the tumor microenvironment.

**Predicted impacts:**
- Altered cell surface glycosylation pattern reducing MHC peptide presentation efficiency
- Preferential recruitment of immunosuppressive macrophages through glycan-lectin interactions
- Decreased recognition by cytotoxic T lymphocytes and NK cells
- Enhanced immune checkpoint engagement (PD-L1 interactions)
- Maintenance of ECM structural integrity supporting tumor architecture
- Protection from complement-mediated lysis

**Supporting genes:** GCNT1, CHSY3

**References:** [35], [44], [47], [54]

**Biological processes:**
- Chondroitin sulfate biosynthesis and deposition: CHSY3
- O-linked glycan biosynthesis in glioblastoma: GCNT1, CHSY3
- Glycosaminoglycan accumulation and immune suppression: GCNT1, CHSY3

**Cellular components:**
- Glycosaminoglycan attachment sites: CHSY3, GCNT1
- Cell surface glycoprotein complexes: GCNT1, CHSY3

**Reference notes:**
- Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation through MGL targeting
- Chondroitin sulfate biosynthetic genes correlate with worse prognosis and immune response alterations
- In-depth cell surface proteomic landscape of HGG ECM identifying glycosylated proteins as immune targets
- EMT-associated glycosylation changes affecting immune recognition

## References
- [10] Notes: NOX4-derived ROS in cancer development and progression
- [12] Notes: Comprehensive review of COX-2 in GBM proliferation, apoptosis, invasion, angiogenesis, and immunosuppression
- [15] Notes: Role of COX-2/PGE2 in angiogenesis and immune regulation in GBM tumor microenvironment | Detailed analysis of COX-2/PGE2 pleotropic effects on glioma-associated microglia dynamics and tumor progression
- [16] Notes: Recent 2024 comprehensive review of MET receptor dysregulation in GBM with targeted therapy strategies
- [17] Notes: 2025 review of Eph/ephrin signaling in CNS tumors, identifying EphA2/A3 as key therapeutic targets
- [18] Notes: COL5A1 is identified as a novel prognostic target and therapeutic target through the PPRC1-ESM1 axis
- [19] Notes: TRIB3 identified as facilitator of GBM progression through autophagy regulation
- [2] Notes: RUNX2 promotes malignant progression in glioma through cross-talk with cAMP/PKA signaling
- [24] Notes: Comprehensive analysis of integrin pathways in GBM metastasis and chemoresistance | Cilengitide-induced autophagy reduces GBM cell survival and enhances radiosensitivity | Comprehensive review of integrin roles in GBM metastasis and chemoresistance | Glut-3 addiction in GSCs as metabolic vulnerability
- [29] Notes: Integrin αvβ3 is therapeutically targetable through cilengitide
- [3] Notes: Foundational review of HIF-1α pathway in gliomas with mechanisms of activation and downstream targets | Detailed mechanism of RTK-mediated HIF-1α stabilization through PI3K/AKT/mTOR pathway
- [31] Notes: Analysis of fatty acid oxidation-related subtypes in cancer showing metabolic shifts and therapy resistance
- [33] Notes: NDRG1 acts as tumor suppressor by inhibiting EMT and promoting E-cadherin expression | Comprehensive review of NDRG1 as critical regulator of differentiation and invasion in GBM
- [35] Notes: Vitronectin is highly expressed ECM component in adult GBM | In-depth cell surface proteomic landscape of HGG ECM identifying glycosylated proteins as immune targets
- [36] Notes: LUCAT1 regulates RAS pathway and ABCB1-mediated drug resistance in malignant glioma
- [37] Notes: Microglia-induced interferon-stimulated genes mediate chemotherapy resistance through STAT1 signaling
- [38] Notes: RCAN2 as p53-regulated gene influencing cancer progression through calcineurin signaling
- [39] Notes: LUCAT1 promotes GSC self-renewal and identified as therapeutic target in GBM
- [44] Notes: EMT-associated glycosylation changes affecting immune recognition
- [47] Notes: O-linked glycan alterations in GBM exploit immune modulation through altered glycocode | Evidence that glioblastomas exploit truncated O-linked glycans for immune evasion through MGL-L ligand accumulation | Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation through MGL targeting
- [48] Notes: ECM stiffness and remodeling drive invasion and metastasis through MMP-mediated degradation
- [5] Notes: Recent 2025 study demonstrating HIF-1α mediated regulation of GBM malignant behaviors with experimental validation
- [54] Notes: Chondroitin sulfate biosynthetic genes correlate with worse prognosis and immune response alterations
- [56] Notes: ERRFI1 differential regulation of EGFR and AKT pathways based on receptor expression level | ERRFI1 dual mechanism in AKT and EGFR pathway regulation based on receptor expression
- [7] Notes: Comprehensive review of HO-1 role in tumorigenesis with dual pro- and anti-survival functions
- [8] Notes: ANGPTL4 promotes anoikis resistance and invasion through integrin β1 signaling and MMP-1 upregulation | ANGPTL4-mediated ROS generation through Nox1 activation
- [9] Notes: Detailed analysis of HIF-1α dependent autophagy induction through BNIP3/BNIP3L axis and immune modulation | Comprehensive review of hypoxia-associated pathways including autophagy induction and immune suppression | HIF-1α modulation of adenosine metabolism affecting immune cell function and tumor progression
